Stephen Bardin - 24 Jun 2025 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Reporting relationship: Chief Financial Officer
Issuer ticker: CALC
Reported as of: 24 Jun 2025
Net transaction value: +$3,005
SEC form: 4
Accepted by SEC: 26 Jun 2025, 18:30:22 UTC
Prior SEC filing: 03 Jun 2025
Next SEC filing: 07 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ John Dunn, Attorney-in-Fact

Key filing fact

Stephen Bardin filed Form 4 for CalciMedica, Inc. (CALC) on 26 Jun 2025.

Key facts

This page summarizes Stephen Bardin's Form 4 filing for CalciMedica, Inc. (CALC).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Jun 2025, 18:30.

Change

Previous filing in this sequence was filed on 03 Jun 2025.
Current net transaction value: +$3,005.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001942596 Primary reporting owner

Bardin Stephen

Relationship: Chief Financial Officer
Address: C/O CALCIMEDICA, INC., 505 COAST S. BLVD, #307, LA JOLLA
Signature: /s/ John Dunn, Attorney-in-Fact
Signature date: 26 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CALC transaction

Common Stock

Purchase

Transaction value: $3,005
Shares: +2,000
Change %: +200%
Price: $1.50
Shares after: 3,000
Date: 26 Jun 2025
Ownership: See Footnote
Footnotes: F1, F2, F3

CALC holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 40,000
Date: 24 Jun 2025
Ownership: Direct
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CALC transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 24 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $1.53
Footnotes: F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The weighted average purchase price for the transaction reported was $1.5025, and the range of prices were between $1.45 and $1.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

Footnote F2

Includes 1,000 shares held by The Bardin Family Trust dated June 4, 2024 (the "Trust") which were inadvertently reported as directly owned on the Form 4 filed with the SEC on June 3, 2025.

Footnote F3

By The Bardin Family Trust dated June 4, 2024.

Footnote F4

Excludes 1,000 shares held by the Trust which were inadvertently reported as directly owned on the Form 4 filed with the SEC on June 3, 2025.

Footnote F5

The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

Footnote F6

Immediately exercisable.